Table 1.
Product | Drug | Carrier components | Company | Stage | Ref. |
---|---|---|---|---|---|
Nab-Paclitaxel (Abraxane) | PTX | Human serum albumin | Abraxis BioScience | FDA and EMA approved | 9 |
Genexol-PM | PTX | Micelle: mPEG-PDLLA | Samyang Biopharm | Approved in Korea | 10 |
Apealea | PTX | Micelle: two isoforms of N-retinoyl-L-cysteic acid Methyl ester sodium salt | Oasmia Pharmaceutical | EMA approved | 11 |
Lipusu | PTX | Liposome: lecithin/cholesterol | Nanjing Luye Sike Pharmaceutical Co. | Phase IV | 12 |
Doxil | DOX | Liposome: HSPC, cholesterol, mPEG-DSPE | Johnson &Johnson | FDA and EMA approved | 13 |
Myocet | DOX | Liposome: phosphatidylcholine, cholesterol | Teva | EMA approved | 14 |
ThermoDox | DOX | Thermosensitive liposomal doxorubicin | MedKoo Biosciences Inc. | Phase III completed | 15 |
Nanoparticle generator | DOX | Porous silicon microparticle with polymeric doxorubicin | / | Planning of phase I | 16 |
NC-6004 | Cisplatin | Micelle: PEG-P(Glu) | Nano Carrier Co. | Phase I/II | 17 |
Lipoplatin | Cisplatin | Liposome: SPC/cholesterol/DPPG/mPEGDSPE | Regulon Inc. | Phase II/III | 18 |
CRLX101 | CPT | PEG-modified β-cyclodextrin | Cerulean Pharma Inc. | Phase II | 19 |
NKTR-102 | Irinotecan | PEG (four-arm) conjugation | Nektar Therapeutics | Phase II | 20 |
Onivyde | Irinotecan | Liposome: DSPC, cholesterol, mPEG-DSPE | Merrimack Pharmaceuticals | Phase II/III | 21 |
DOTAP: Chol-TUSC2 | TUSC2 | DOTAP: Chol | Genprex, Inc. | Phase I/II | 22 |
Mepact | Mifamurtide | Liposome: POPC,OOPS | Takeda Pharmaceutical | EMA approved | 23 |
Marqibo | Vincristine sulfate | Liposome: sphingomyelin, cholesterol | Talon Therapeutics | FDA approved | 24 |
Vyxeos | Cytarabine and daunorubicin |
Liposome: DSPC,DSPG, cholesterol | Jazz Pharmaceuticals | FDA and EMA approved | 25 |